Everything below concerns peptide fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
== History == This method was developed by Solomon Berson and Rosalyn Sussman Yalow at the Veterans Administration Hospital in the Bronx, New York. This revolutionary development earned Dr. Yalow the Nobel Prize for Medicine in 1977, the second woman ever to win it. In her acceptance speech, Dr. Yalow said, "The world cannot afford the loss of the talents of half its people if we are to solve the many problems which beset us." Yalow shared the Nobel Prize with Roger Guillemin, and Andrew Schally who earned the prize based on their research into "the peptide hormone production of the brain".
However, apart from the population of Na/K-ATPase in the plasma membrane, responsible for ion transport, there is another population in the caveolae which acts as digitalis receptor and stimulates the EGF receptor.
== Sources == Hyaluronic acid can be made through three main processes: Animal sources, Microbial hyaluronic acid production and chemical synthesis. HA was originally extracted from bovine vitreous humor (gel from a cows eye) by Meyer and Palmer in 1934. HA was then also isolated from Pig skin, Human skin and rooster’s comb. The most common animal source is rooster’s comb due being a byproduct from the meat industry. However, challenges such as low yields, high production costs, and ethical issues associated with animal-derived HA has driven the development of microbial production methods for HA.
== History == Sarcosine was first isolated and named by the German chemist Justus von Liebig in 1847. Jacob Volhard first synthesized it in 1862 while working in the lab of Hermann Kolbe. Prior to the synthesis of sarcosine, it had long been known to be a hydrolysis product of creatine, a compound found in meat extract. Under this assumption, by preparing the compound with methylamine and monochloroacetic acid, Volhard proved that sarcosine was N-methylglycine.
Portland cement, the most common type of cement in general use around the world as a basic ingredient of concrete, mortar, stucco, and non-speciality grout, was developed in England in the mid 19th century, and usually originates from limestone. James Frost produced what he called "British cement" in a similar manner around the same time, but did not obtain a patent until 1822. In 1824, Joseph Aspdin patented a similar material, which he called Portland cement, because the render made from it was in color similar to the prestigious Portland stone quarried on the Isle of Portland, Dorset, England. However, Aspdins' cement was nothing like modern Portland cement but was a first step in its development, called a proto-Portland cement. Joseph Aspdins' son William Aspdin had left his father's company and in his cement manufacturing apparently accidentally produced calcium silicates in the 1840s, a middle step in the development of Portland cement. William Aspdin's innovation was counterintuitive for manufacturers of "artificial cements", because they required more lime in the mix (a problem for his father), a much higher kiln temperature (and therefore more fuel), and the resulting clinker was very hard and rapidly wore down the millstones, which were the only available grinding technology of the time. Manufacturing costs were therefore considerably higher, but the product set reasonably slowly and developed strength quickly, thus opening up a market for use in concrete.
Sources: en.wikipedia.org
== Career == In 1953 he was elected to a Life Fellowship at King's, where he remained for the whole of his academic career, holding the positions of Financial Tutor (1956–1959), Director of Studies in Natural Sciences (1961–1981), Vice Provost (1981–1986) and Praelector (1989–1992), as well as co-editor of the College Register. In 1954 he was appointed as University Demonstrator in biochemistry, and in 1959 was promoted to University Lecturer. From 1964 to 1965, he worked at the Engelhardt Institute of Molecular Biology in Moscow as part of a UK-USSR exchange program. Dixon was an editor of The Biochemical Journal, and was Deputy Chairman of the Editorial Board from 1977 to 1982. He was secretary of the Nomenclature Committee of the International Union of Biochemistry from 1977 to 1982 and chairman from 1983 to 1988, and after his retirement remained an advisory member. Dixon's research in chemistry and biochemistry led to 136 published papers. His interests included the pH-dependence of enzyme-catalysed reactions, arsenic biochemistry, protein modification and other aspects of enzymology. His particular interest in applications of methods from organic chemistry to biochemistry led to a proposed treatment for Wilson's disease. In 1957 he married Heather Spittle with whom he had three children. After his death, a set of rooms in the Gibbs' Building in King's College was named the Hal Dixon Rooms in his memory.
The FDA trade union which represents senior civil servants launches its High Court case against the UK government over the Rwanda asylum plan, arguing that they could be asked to break the law by ministers if they were asked to ignore a ruling from the European Court of Human Rights to halt a flight to Rwanda. Labour abandons legal action against five Corbyn-era employees who were accused of "conspiring" against Keir Starmer's leadership. It is revealed that the Conservatives accepted a further donation from Frank Hester after he was accused of making racist comments about Diane Abbott. 7 June – The legal deadline for candidates in the general election passes. Rishi Sunak apologises for leaving the D-day memorial early to return to the UK to give an ITV interview about the election. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Keith Vaz, who stood down from Parliament after he was found to have "expressed willingness" to buy cocaine for male prostitutes, will stand in his old Leicester East constituency for the One Leicester Party. Mishal Husain moderates the first of the BBC's election debates featuring representatives from seven of the UK's political parties. Appearing on the programme are Penny Mordaunt (Conservative), Angela Rayner (Labour), Daisy Cooper (Liberal Democrats), Stephen Flynn (SNP), Rhun ap Iorwerth (Plaid Cymru), Carla Denyer (Green) and Nigel Farage (Reform UK). The Unite trade union says it will not endorse Labour's election manifesto because it does not go far enough on protecting the rights of workers.
Adenylyl-sulfate reductase (glutathione) (EC 1.8.4.9) is an enzyme that catalyzes the chemical reaction AMP + sulfite + glutathione disulfide ⇌ {\displaystyle \rightleftharpoons } adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
=== Modern reception === Bloodlines is considered a cult classic. Retrospective critiques continue to praise the game's narrative and degree of choice. In 2009, an article in Rock, Paper, Shotgun declared: "The sense of sorrow comes from the realization that there's nothing like [Bloodlines] on the horizon ... why should there be so few games like this? Oh right, because it's so very hard to do ... the lack of games comparable to Bloodlines is one of the great tragedies of our time." Eurogamer called the game inspirational, with an unmatched level of narrative detail. In 2010, The Escapist called Bloodlines a flawed masterpiece which could have been a genuine masterpiece with more time, money, and staff; although great games may inspire awe, it instead created a devoted fan base which continued to develop the game. In 2006, PC Zone listed Bloodlines the seventh-best PC game which people were unlikely to have played, calling it the "best buggy game ever released". In 2007, the game was 80th on Computer & Video Games' list of its top 100 games, and 86th on PC Gamer's 2014 list of the same; it also appeared in PC Gamer's 2015 edition (moving to 63rd), 2017 edition (moving to 42nd), and 2021 edition (moving to 93rd). In 2008, bit-tech listed Jeanette as the second-best non-player video game character. In 2011, Rock, Paper, Shotgun called Bloodlines one of the most important PC games of all time ("it signposts a direction to a future of games that we were denied"), listing it as one of the 122 Best PC Games Ever.
This excretion of glucose in the urine, which does not seem to disturb other blood electrolytes, is accompanied by some diuresis which may be what contributes to many other physiological functions, potentially explaining its place in heart failure treatment. Empagliflozin was approved for medical use in the United States and in the European Union in 2014. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 34th most commonly prescribed medication in the United States, with more than 16 million prescriptions. It received approval as a generic medication from the US Food and Drug Administration (FDA) in 2022.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.